Moxifloxacin Pharmathen (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Pharmathen, is a fluoroquinolone antibiotic presented as an oral dosage form for oral use. It treats community‑acquired bacterial pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, skin and skin structure infections, and intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacin Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to manage bacterial infections in several organ systems.

- Community‑acquired bacterial pneumonia: achieves clinical cure and bacterial eradication. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute bacterial exacerbation of chronic bronchitis: improves airflow and resolves infection. - Skin and skin structure infections: clears bacterial involvement and promotes healing. - Intra‑abdominal infections: controls polymicrobial infection and supports recovery.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Abdominal pain: cramping or discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or loss of function. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile infection: severe colitis. - Hepatic toxicity: elevated liver enzymes or jaundice. - Stevens‑Johnson syndrome: severe mucocutaneous reaction.

Moxifloxacin requires careful assessment before and during therapy. - Renal function assessment: adjust use in impaired clearance. - QT interval monitoring: avoid in patients with known prolongation. - Hypersensitivity screening: discontinue if allergic reaction occurs. - Elderly caution: increased risk of tendon injury. - Concomitant QT‑prolonging drugs: avoid combined use. - Store at room temperature: keep in original container, protect from moisture and light.

Moxifloxacin interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Systemic corticosteroids: heightened risk of tendon rupture. - Other fluoroquinolones: additive toxicity, avoid co‑administration. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): may cause serious cardiac arrhythmias. - Antacids containing magnesium or aluminum: reduce oral absorption of moxifloxacin.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, monitor coagulation. - Theophylline: potential increase in serum levels, watch for toxicity. - Cyclosporine: may raise cyclosporine concentrations, adjust dosing as needed.